Skip to main content

Table 1 Clinicopathological features of 157 patients with stage III colorectal cancer

From: High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer

 

All, n = 157 (%)

Age, years

63.0 (56.0–70.0)

Gender

 Female

71 (45.2)

 Male

86 (54.8)

Location

 Colon

83 (52.9)

 Rectum

74 (47.1)

Preoperative CEA level

  ≤ 5 ng/ml

89 (56.7)

  > 5 ng/ml

68 (43.3)

Histological type

 Well- or moderately differentiated

150 (95.5)

 Poorly differentiated

7 (4.5)

Tumour invasion

 T1

2 (1.3)

 T2

25 (15.9)

 T3

108 (68.8)

 T4

22 (14.0)

Lymph node status

 N1a

111 (70.7)

 N1b

6 (3.8)

 N1c

4 (2.6)

 N2a

24 (15.3)

 N2b

12 (7.6)

Stage

 IIIA

22 (14.0)

 IIIB

120 (76.4)

 IIIC

15 (9.6)

Adjuvant chemotherapy

 No

32 (20.4)

 Yes

125 (79.6)

Follow-up, months

66.0 (51.5–84.0)